Thermo Fisher Scientific Inc. DEF 14A Filing

Ticker: TMO · Form: DEF 14A · Filed: Apr 9, 2024 · CIK: 97745

Thermo Fisher Scientific Inc. DEF 14A Filing Summary
FieldDetail
CompanyThermo Fisher Scientific Inc. (TMO)
Form TypeDEF 14A
Filed DateApr 9, 2024
Risk Levellow
Pages14
Reading Time17 min
Key Dollar Amounts$42.86 b, $15.45, $21, $7.01 billion, $3.5 billion
Sentimentneutral

Sentiment: neutral

Topics: DEF 14A, Thermo Fisher Scientific, Executive Compensation, Stock Options, Restricted Stock Units

TL;DR

<b>Thermo Fisher Scientific files its DEF 14A, detailing executive compensation and stock award valuations.</b>

AI Summary

THERMO FISHER SCIENTIFIC INC. (TMO) filed a Proxy Statement (DEF 14A) with the SEC on April 9, 2024. The filing is a Definitive Proxy Statement (DEF 14A) for Thermo Fisher Scientific Inc. It details executive compensation, including stock option and restricted stock unit grants. Fair values for stock options are calculated using the Black-Scholes model. Performance-based RSUs are valued assuming target performance, with adjustments for stock price and performance modifiers. Time-based RSUs are valued based on the stock price at the grant date and vesting dates.

Why It Matters

For investors and stakeholders tracking THERMO FISHER SCIENTIFIC INC., this filing contains several important signals. This filing provides transparency into how executive compensation is structured and valued, particularly concerning stock-based awards. Understanding these valuations is crucial for shareholders to assess executive incentives and potential dilution from stock awards.

Risk Assessment

Risk Level: low — THERMO FISHER SCIENTIFIC INC. shows low risk based on this filing. The filing is a routine DEF 14A, providing standard disclosures on executive compensation and does not contain new material financial information or significant strategic shifts.

Analyst Insight

Review the executive compensation details and stock award valuations to understand potential impacts on shareholder value and dilution.

Key Numbers

  • 2024-05-22 — Conformed Period of Report
  • 2024-04-09 — Filed as of Date
  • 1231 — Fiscal Year End

Key Players & Entities

  • THERMO FISHER SCIENTIFIC INC. (company) — Filer
  • Thermo Electron Corp (company) — Former company name

FAQ

When did THERMO FISHER SCIENTIFIC INC. file this DEF 14A?

THERMO FISHER SCIENTIFIC INC. filed this Proxy Statement (DEF 14A) with the SEC on April 9, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by THERMO FISHER SCIENTIFIC INC. (TMO).

Where can I read the original DEF 14A filing from THERMO FISHER SCIENTIFIC INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by THERMO FISHER SCIENTIFIC INC..

What are the key takeaways from THERMO FISHER SCIENTIFIC INC.'s DEF 14A?

THERMO FISHER SCIENTIFIC INC. filed this DEF 14A on April 9, 2024. Key takeaways: The filing is a Definitive Proxy Statement (DEF 14A) for Thermo Fisher Scientific Inc.. It details executive compensation, including stock option and restricted stock unit grants.. Fair values for stock options are calculated using the Black-Scholes model..

Is THERMO FISHER SCIENTIFIC INC. a risky investment based on this filing?

Based on this DEF 14A, THERMO FISHER SCIENTIFIC INC. presents a relatively low-risk profile. The filing is a routine DEF 14A, providing standard disclosures on executive compensation and does not contain new material financial information or significant strategic shifts.

What should investors do after reading THERMO FISHER SCIENTIFIC INC.'s DEF 14A?

Review the executive compensation details and stock award valuations to understand potential impacts on shareholder value and dilution. The overall sentiment from this filing is neutral.

How does THERMO FISHER SCIENTIFIC INC. compare to its industry peers?

Thermo Fisher Scientific operates in the life sciences and laboratory products industry, a sector characterized by innovation and significant R&D investment.

Are there regulatory concerns for THERMO FISHER SCIENTIFIC INC.?

Companies are required to file DEF 14A statements to provide shareholders with information necessary to make informed voting decisions, particularly concerning executive compensation and corporate governance.

Industry Context

Thermo Fisher Scientific operates in the life sciences and laboratory products industry, a sector characterized by innovation and significant R&D investment.

Regulatory Implications

Companies are required to file DEF 14A statements to provide shareholders with information necessary to make informed voting decisions, particularly concerning executive compensation and corporate governance.

What Investors Should Do

  1. Analyze the specific stock option and RSU grant details for Named Executive Officers (NEOs).
  2. Compare the valuation methodologies and assumptions used for different award types.
  3. Assess the potential dilutive effect of stock awards on existing shareholders.

Glossary

DEF 14A
Definitive Proxy Statement (This filing provides detailed information to shareholders regarding matters to be voted on at the annual meeting, including executive compensation.)
Black-Scholes option pricing model
A mathematical model used to estimate the theoretical price of stock options. (Used by Thermo Fisher to calculate the fair value of stock option grants, impacting executive compensation disclosures.)
Restricted Stock Unit (RSU)
A grant of stock that vests over time or upon meeting certain performance conditions. (A key component of executive compensation at Thermo Fisher, with specific valuation methods detailed in the filing.)

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard annual disclosure. No specific comparison to a prior filing's content is available from the provided text.

Filing Stats: 4,246 words · 17 min read · ~14 pages · Grade level 16.6 · Accepted 2024-04-09 07:16:58

Key Financial Figures

  • $42.86 b — d performance. This included revenue of $42.86 billion, GAAP diluted earnings per share
  • $15.45 — AAP diluted earnings per share (EPS) of $15.45 and adjusted EPS* of $21.55, along with
  • $21 — re (EPS) of $15.45 and adjusted EPS* of $21.55, along with free cash flow* of $7.01
  • $7.01 billion — f $21.55, along with free cash flow* of $7.01 billion. In addition, we returned significant c
  • $3.5 billion — ant capital to our shareholders through $3.5 billion of stock buybacks and dividends. At t
  • $1.3 billion — ommercial engine In 2023, we invested $1.3 billion in R&D to deliver new technologies acro
  • $40B — mprehensive pharma services offering >$40B revenue >120,000 colleagues $1.3B
  • $1.3B — >$40B revenue >120,000 colleagues $1.3B R&D investment Our Mission is our pu
  • $3.0B — ompared to 2022 140% Five-Year TSR $3.0B 2023 Share Repurchases * Adjusted E

Filing Documents

Executive compensation

Executive compensation 30 PROPOSAL 2 Approval of an advisory vote on executive compensation 30 Compensation discussion and analysis 30 Executive summary 32 Compensation Committee report 51

Executive compensation tables

Executive compensation tables 52 CEO pay ratio 62 Pay versus performance 62 Audit matters 65 PROPOSAL 3 Ratification of the selection of the independent auditors 65 Review and engagement 65 Independent auditor fees 65 Audit Committee's pre-approval policies and procedures 66 Audit Committee report 66 Shareholder proposal 67 PROPOSAL 4 Shareholder proposal 67 Information about stock ownership 69

Security ownership of certain beneficial owners and management

Security ownership of certain beneficial owners and management 69 Equity compensation plan information 70 Voting and meeting information 71 Virtual annual meeting 71 Voting information 71 Proxy solicitation and distribution 73 Submitting 2025 proposals 74 Appendix A: Reconciliation of GAAP to non-GAAP financial measures 75 Frequently Requested Information Annual Compensation Setting Process 48 Board Diversity 16 Board Leadership Structure 19 Board Self-Evaluation 17 Board Skills and Experience 10 CEO Pay Ratio 62 Clawback Policy 51 Committees of the Board 20 Components of Our Compensation Program 35 Named Executive Officers 30 Overboarding Policy 26 Oversight of Cybersecurity and Information Technology 24 Oversight of ESG 24 Oversight of Risk and Strategy 22 Peer Group 49 Policy on Hedging and Pledging 51 Shareholder Engagement Program 7 Stock Ownership Guidelines 50 Summary Compensation Table 52 Thermo Fisher Scientific Inc. 168 Third Avenue, Waltham, MA 02451 USA thermofisher.com thermofisher.com 2024 Proxy Statement 3 Company overview Who we are Thermo Fisher Scientific Inc. (also referred to in this document as "Thermo Fisher," "we," "us," "our," and the "Company") is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.